Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 370

1.

Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated.

Skull SA, Andrews RM, Byrnes GB, Kelly HA, Nolan TM, Brown GV, Campbell DA.

Vaccine. 2007 Jun 6;25(23):4631-40. Epub 2007 Mar 26.

PMID:
17478015
2.

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up.

Hedlund J, Christenson B, Lundbergh P, Ortqvist A.

Vaccine. 2003 Sep 8;21(25-26):3906-11.

PMID:
12922125
3.

Hospitalized community-acquired pneumonia in the elderly: an Australian case-cohort study.

Skull SA, Andrews RM, Byrnes GB, Campbell DA, Kelly HA, Brown GV, Nolan TM.

Epidemiol Infect. 2009 Feb;137(2):194-202. doi: 10.1017/S0950268808000812. Epub 2008 Jun 18.

PMID:
18559126
4.

Effectiveness of pneumococcal polysaccharide vaccine in older adults.

Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW; Vaccine Safety Datalink.

N Engl J Med. 2003 May 1;348(18):1747-55.

5.

Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.

Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C; EVAN Study Group.

Clin Infect Dis. 2006 Oct 1;43(7):860-8. Epub 2006 Aug 21.

PMID:
16941367
6.

Missed opportunities to vaccinate a cohort of hospitalised elderly with pneumococcal and influenza vaccines.

Skull SA, Andrews RM, Byrnes GB, Kelly HA, Nolan TM, Brown GV, Campbell DA.

Vaccine. 2007 Jul 9;25(28):5146-54. Epub 2007 May 21.

PMID:
17543426
7.

Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older.

Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Läärä E, Leinonen M, Kivelä SL, Mäkelä PH.

Vaccine. 1999 Jun 4;17(20-21):2493-500.

PMID:
10418894
8.

Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.

Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, Iwanaga K, Yamaryo T, Oishi K.

Vaccine. 2010 Oct 8;28(43):7063-9. doi: 10.1016/j.vaccine.2010.08.010. Epub 2010 Aug 17.

PMID:
20723631
9.
10.

Pneumococcal vaccine in the elderly: a useful but forgotten vaccine.

Chidiac C, Ader F.

Aging Clin Exp Res. 2009 Jun;21(3):222-8. Review.

PMID:
19571646
11.

Bacterial carriage and respiratory tract infections in subjects > or = 60 years during an influenza season: implications for the epidemiology of community acquired pneumonia and influenza vaccine effectiveness.

Ansaldi F, De Florentiis D, Parodi V, Rappazzo E, Coppelli M, Martini M, Alicino C, Durando P, Icardi G.

J Prev Med Hyg. 2012 Jun;53(2):94-7.

PMID:
23240167
12.

Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.

Johnstone J, Marrie TJ, Eurich DT, Majumdar SR.

Arch Intern Med. 2007 Oct 8;167(18):1938-43.

PMID:
17923592
13.

Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia.

Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J.

Clin Infect Dis. 2006 Apr 15;42(8):1093-101. Epub 2006 Mar 13.

PMID:
16575726
14.
15.

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.

Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X.

Vaccine. 2009 Mar 4;27(10):1504-10. doi: 10.1016/j.vaccine.2009.01.013. Epub 2009 Jan 24.

PMID:
19171174
16.

[Prevention of community-acquired pneumonia in adults].

Barros M M, Cartagena S C, Bavestrello F L.

Rev Chilena Infectol. 2005;22 Suppl 1:s67-74. Epub 2005 Sep 13. Review. Spanish.

17.

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.

Nichol KL, Baken L, Wuorenma J, Nelson A.

Arch Intern Med. 1999 Nov 8;159(20):2437-42.

PMID:
10665892
18.
19.
20.

Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.

Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez M, Saez M, Soldevila N, Astray J, Mayoral JM, Martín V, Quintana JM, González-Candelas F, Galán JC, Tamames S, Castro A, Baricot M, Garín O, Pumarola T; CIBERESP Cases and Controls in Pandemic Influenza Working Group (Spain).

Hum Vaccin Immunother. 2013 Apr;9(4):865-73. doi: 10.4161/hv.23090. Epub 2013 Apr 1.

Supplemental Content

Support Center